60. Aplastic anemia Clinical trials / Disease details
Clinical trials : 235 / Drugs : 381 - (DrugBank : 83) / Drug target genes : 44 - Drug target pathways : 160
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100047288 | 2021-06-01 | 2021-06-11 | Efficacy and safety of combined immunosuppressive therapy plus umbilical cord blood infusion in myelodysplastic syndromes/aplastic anemia patients: a clinical observation study | Efficacy and safety of combined immunosuppressive therapy plus umbilical cord blood infusion in myelodysplastic syndromes/aplastic anemia patients: a clinical observation study | myelodysplastic syndromes/aplastic anemi | Experimental group1:According to the classification, ATG + CsA/CSA alone is used as the pretreatment plan/supportive treatment + non-blood cord blood stem cell infusion treatment;Experimental group2:Decitabine+cytarabine/decitabine alone is used as the pretreatment plan/supportive treatment+non-blood cord blood stem cell infusion treatment according to the classification; | The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital) | NULL | Recruiting | 18 | 90 | Both | Experimental group1:10;Experimental group2:10; | China | |
| 2 | NCT00578903 (ClinicalTrials.gov) | February 2002 | 19/12/2007 | Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia | Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia, Using Matched Unrelated Donors and Mismatched Related Donors (SAA MUD) | Aplastic Anemia | Drug: Cytoxan;Drug: Campath;Radiation: Total Body Irradiation (TBI);Drug: FK-506;Drug: Methotrexate;Procedure: Stem cell infusion | Baylor College of Medicine | The Methodist Hospital System;Texas Children's Hospital;Center for Cell and Gene Therapy, Baylor College of Medicine | Terminated | N/A | 60 Years | All | 22 | Phase 2 | United States |
| 3 | NCT00590460 (ClinicalTrials.gov) | July 2001 | 26/12/2007 | Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia | Cd45 (Yth-24 and Yth 54) and Cd52 (Campath-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell Transplantation of Patients With Fanconi Anemia | Fanconi Anemia;Severe Aplastic Anemia | Biological: CAMPATH-1H;Biological: Anti-CD45;Drug: Fludarabine;Procedure: Stem cell infusion | Baylor College of Medicine | The Methodist Hospital System;Center for Cell and Gene Therapy, Baylor College of Medicine | Terminated | N/A | N/A | All | 5 | Phase 1/Phase 2 | United States |